Long-Term Safety and Aesthetics of Ellanse via Multi-Cancer Early Detection (MCED) and 7-point Global Aesthetic Improvement Score (GAIS)
Journal of Regenerative Medicine and Biology Research · 2026
DOI: 10.46889/jrmbr.2026.7304 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Regenerative Medicine and Biology Research, 2026. Verfasst von Larry Wu und 3 weiteren Autor:innen. Die Arbeit nennt 24 Literaturangaben.
Abstract (Originalsprache)
Introduction
Ellanse is a polycaprolactone based biostimulator that has a dual mode of action: the immediate aesthetic result due to carboxymethylcellulose gel followed by polycaprolactone mediated neocollagenesis. Ellanse has 2 different preparations: Ellanse S, which has a product longevity of 12 to 18 months and Ellanse M, which has a product longevity of 24 months. The long-term health and aesthetic effect of prolonged polycaprolactone microsphere treatment is unknown.
Methods
A retrospective case series of six patients (5 female and 1 male) who had previously received an average of 31.3 syringes of Ellanse M each from 2017 to 2026 underwent Multi-Cancer Early Detection (MCED – liquid biopsy) blood test evaluation. MCED is a targeted mutation-based liquid biopsy test that sequences circulating tumour DNA (ctDNA) for women (14 categories, 55 cancer types) and men (11 categories, 31 cancer types). The overall sensitivity is 83.1% and specificity is 95.4%. Aesthetic assessment is performed by 7-Point Likert Global Aesthetic Improvement Score (GAIS) evaluation based on their initial presentation and current state in 2026.
Results
The average age of patient is 63.3 years (standard deviation SD: 12.2 year) and the number of years treated is 8 years (SD 1.1). The MCED test is negative for ctDNA for all 6 patients, indicating long term treatment for Ellanse is safe in terms of oncogenesis potential. In addition, the 7-point GAIS improved by an average of 1.9 (more than 8 years) after their initial consultation. The result is statistically significant based on Wilcoxon Signed Rank test at 0.05 level of significance. The patients did not report any nodule formation or incidence of vascular compromise.
Conclusion
Ellanse represents a class of collagen stimulators that is safe in terms of oncogenic potential and it improves the 7-point GAIS by more than 1.9 more than average 8 years after initial treatment.
Zitieren
APA
Wu, L., Chua, Z. X., Wang, M., & Soh, P. (2026). Long-Term Safety and Aesthetics of Ellanse via Multi-Cancer Early Detection (MCED) and 7-point Global Aesthetic Improvement Score (GAIS). Journal of Regenerative Medicine and Biology Research. https://doi.org/10.46889/jrmbr.2026.7304
Vancouver
Wu L, Chua ZX, Wang M, Soh P. Long-Term Safety and Aesthetics of Ellanse via Multi-Cancer Early Detection (MCED) and 7-point Global Aesthetic Improvement Score (GAIS). Journal of Regenerative Medicine and Biology Research. 2026. doi:10.46889/jrmbr.2026.7304
BibTeX
@article{Wu2026,
author = {Wu, Larry and Chua, Zhuo Xun and Wang, Mingzhe and Soh, Peilin},
title = {Long-Term Safety and Aesthetics of Ellanse via Multi-Cancer Early Detection (MCED) and 7-point Global Aesthetic Improvement Score (GAIS)},
journal = {Journal of Regenerative Medicine and Biology Research},
year = {2026},
doi = {10.46889/jrmbr.2026.7304}
}
EUVIMED